摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-巯基-5-硝基苯并噁唑 | 22876-21-7

中文名称
2-巯基-5-硝基苯并噁唑
中文别名
2-巯基-5-硝基苯并恶唑;5-硝基苯并噁唑并-2-硫酮
英文名称
5-nitrobenzoxazoline-2-thione
英文别名
4-nitro-1,3-benzoaxazolidine-2-thione;5-nitrobenzoxazole-2-thiol;5-nitrobenzo[d]oxazole-2(3H)-thione;1-nitrobenzo[d]oxazole-2(3H)-thione;5-nitro-3H-benzooxazole-2-thione;5-nitro-3H-benzoxazole-2-thione;5-Nitrobenzoxazolin-2-thion;5-Nitrobenzoxazolinthion;5-Nitro-benzoxazolthion;5-Nitro-3H-benzoxazol-2-thion
2-巯基-5-硝基苯并噁唑化学式
CAS
22876-21-7
化学式
C7H4N2O3S
mdl
MFCD00524789
分子量
196.186
InChiKey
FQOGSTGLRLMQOV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    244-245 °C
  • 沸点:
    326.7±44.0 °C(Predicted)
  • 密度:
    1.65±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    99.2
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    2-8°C

SDS

SDS:e1ff360d8d77b57ff42da6f7c5beaa4e
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 5-Nitro-3H-1,3-benzoxazole-2-thione
Synonyms: 5-Nitro-1,3-benzoxazole-2-thiol

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 5-Nitro-3H-1,3-benzoxazole-2-thione
CAS number: 22876-21-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4N2O3S
Molecular weight: 196.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Analgesic Compounds, Compositions, and Uses Thereof
    摘要:
    这项发明涉及化合物、组合物和方法,用于减轻需要的受试者的疼痛,包括给予所述的化合物和组合物。
    公开号:
    US20110224269A1
  • 作为产物:
    描述:
    2,4-二硝基酚氢氧化钾氢气 作用下, 以 乙醇 为溶剂, 生成 2-巯基-5-硝基苯并噁唑
    参考文献:
    名称:
    Regulatory molecules for the 5-HT3 receptor ion channel gating system
    摘要:
    Substituted benzoxazole derivatives which possess a nitrogen containing heterocycle at C2 are selective partial agonists of the 5-HT3 receptor. Alteration of substituents on the benzoxazole nucleus affords both agonist-like and antagonist-like compounds, and uniquely modifies the function of the 5-HT3 receptor ion channel gating system. SAR and corroborative computational docking study for these partial agonists successfully explained structure and function of the 5-HT3 receptor. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2007.02.054
点击查看最新优质反应信息

文献信息

  • Synthesis and anticancer activity evaluation of N-[4-(2-methylthiazol-4-yl)phenyl]acetamide derivatives containing (benz)azole moiety
    作者:Leyla Yurttaş、Yusuf Özkay、Gülşen Akalın-Çiftçi、Şafak Ulusoylar-Yıldırım
    DOI:10.3109/14756366.2013.763253
    日期:2014.4.1
    investigate their anticancer activity. The structure of the compounds was confirmed by IR, (1)H-NMR, and MS spectral data and elemental analyses. Anticancer effect of the compounds was evaluated against A549 and C6 tumor cell lines. MTT, analysis of DNA synthesis, acridine orange/ethidium bromide staining method and analysis of caspase-3 activation assays were performed for anticancer activity investigations
    合成了一类新型的新型噻唑-(苯并)唑衍生物以研究其抗癌活性。化合物的结构通过IR,(1)H-NMR和MS光谱数据以及元素分析确认。评价了化合物对A549和C6肿瘤细胞系的抗癌作用。进行了MTT,DNA合成分析,a啶橙/化乙锭染色方法和caspase-3活化分析,以进行抗癌活性研究。带有5-5-甲基苯并咪唑基的化合物6f和6g显示出显着的抗癌活性。还观察到这些化合物将肿瘤细胞引导至凋亡途径的潜力,这是抗癌作用的前提。
  • Benzoxazolamines and Benzothiazolamines: Potent, Enantioselective Inhibitors of Leukotriene Biosynthesis with a Novel Mechanism of Action
    作者:Edward S. Lazer、Clara K. Miao、Hin-Chor Wong、Ronald Sorcek、Denice M. Spero、Alex Gilman、Kollol Pal、Mark Behnke、Anne G. Graham
    DOI:10.1021/jm00033a008
    日期:1994.4
    phenylalanine with a cyclohexyl group greatly enhance potency. Several ester bioisosteres that retain potency and enantiomeric selectivity are described. Lead optimization culminated in (S)-N-[2-cyclohexyl-1-(2-pyridinyl)ethyl]-5-methyl-2-benzoxazolamine+ ++ (43b), IC50 0.001 microM. The compounds described are not inhibitors of 5-lipoxygenase but, rather, act at the level of arachidonic acid release.
    描述了一系列抑制白三烯(LT)生物合成的苯并恶唑胺苯并噻唑胺类似物。最初的(S)-N-(苯并噻唑-2-基)苯丙氨酸乙酯(5a)在筛选程序中被发现,该程序可抑制Ca-离子载体-A23187诱导的人多形核白细胞释放LTB4(IC50 0.23 microM )。通过结构修饰,确定了5-位上的疏取代基以及苯丙酸的苯环被环己基取代极大地增强了效能。描述了几种保留效力和对映异构体选择性的酯类生物甾体。优化最终达到(S)-N- [2-环己基-1-(2-吡啶基)乙基] -5-甲基-2-苯并恶唑胺+ ++(43b),IC50 0.001 microM。所述化合物不是5-脂氧合酶的抑制剂,而是
  • An environmentally benign and efficient synthesis of substituted benzothiazole-2-thiols, benzoxazole-2-thiols, and benzimidazoline-2-thiones in water
    作者:Xing Liu、Min Liu、Wan Xu、Meng-Tian Zeng、Hui Zhu、Cai-Zhu Chang、Zhi-Bing Dong
    DOI:10.1039/c7gc02311a
    日期:——
    An efficient and practical method for the one-step synthesis of benzothiazole-2-thiols, benzoxazole-2-thiols and benzimidazoline-2-thiones by cyclization of 2-aminothiophenols, 2-aminophenols, and 1,2-phenylenediamines with tetramethylthiuram disulfide (TMTD) in water was described. The features of this method include metal/ligand-free, excellent yield, short reaction time and broad substrate scope
    一种有效而实用的方法,是通过将2-,2-和1,2-苯二胺与四甲基秋兰姆硫化物环化,一步一步合成苯并噻唑-2-醇,苯并恶唑-2-醇和苯并咪唑啉-2-酮(描述了在中的TMTD。该方法的特点包括无属/配体,优异的产率,较短的反应时间和广泛的底物范围。该方法提供了一些潜在的生物活性化合物的简便的制备方法。
  • Benzothiazole, thiazolopyridine, benzooxazole and oxazolopyridine derivatives
    申请人:Binggeli Alfred
    公开号:US20060205718A1
    公开(公告)日:2006-09-14
    This invention is concerned with compounds of the formula wherein A, B 1 , B 2 , R 1 , R 2 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.
    这项发明涉及以下式的化合物 其中A、B 1 、B 2 、R 1 、R 2 和G如描述和索赔中所定义,并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物,以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
  • Design, synthesis and pharmacology of aortic-selective acyl-CoA: Cholesterol O-acyltransferase (ACAT/SOAT) inhibitors
    作者:Kimiyuki Shibuya、Katsumi Kawamine、Toru Miura、Chiyoka Ozaki、Toshiyuki Edano、Ken Mizuno、Yasunobu Yoshinaka、Yoshihiko Tsunenari
    DOI:10.1016/j.bmc.2018.06.024
    日期:2018.8
    lipid-accumulation areas in the aortic arch to 74 and 69%, respectively without reducing the plasma total cholesterol level in high fat- and cholesterol-fed F1B hamsters. Here, we demonstrate the antiatherosclerotic effect of 3h in vivo via its direct action on aortic ACAT and its powerful modulator of cholesterol level. This molecule is a potential therapeutic agent for the treatment of diseases involving ACAT-1
    我们描述了我们的主动脉选择性酰基辅酶A胆固醇O-酰基转移酶(ACAT,也缩写为SOAT)抑制剂的分子设计,其结构-活性关系(SARs)以及它们的药代动力学(PK)和药理学特征。两个弱配体-N-(2,6-二异丙基苯基)乙酰胺(50%抑制浓度[IC 50 ] = 8.6μM)和2-(甲基)苯并[ d ]恶唑(IC 50  = 31μM)的连接包括6支亚甲基链的连接体,得到一种高度有效分子,9-(苯并[ d ]恶唑-2-基基) - ñ - (2,6-二异丙基)壬酰胺(3H),其表现出高效力(IC 50 = 0.004μM)朝向主动脉ACAT。这种从头到尾的设计使将活性显着提高到2150至7750倍,并基于双重诱导的拟合机制来区分同工型选择性成为可能。在1 mg / kg和3 mg / kg的剂量下,3h显着降低了主动脉弓的脂质蓄积面积,分别降至74%和69%,而没有降低高脂和高胆固醇喂养的F
查看更多

同类化合物

(N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) 钙离子载体A23187半镁盐 钙离子载体A23187半钙盐 萘并[2,3-d]噁唑-2,8(3H,5H)-二酮,6,7-二氢-5-甲基- 萘并[2,3-d]噁唑-2,5-二酮,3,6,7,8-四氢-3,8-二甲基- 荧光增白剂EBF 苯并恶唑胺 苯并恶唑的取代物 苯并恶唑甲磺酰氯 苯并恶唑基-2-甲酰基-S-乙基-异缩氨基硫脲 苯并恶唑-2-羧酸酰肼 苯并恶唑-2-磺酸 苯并恶唑-2-甲酸 苯并恶唑-2-甲磺酸钠 苯并恶唑-2-乙酸 苯并恶唑 苯并噁唑-5-甲酸 苯并噁唑-2-羧酸乙酯 苯并噁唑-2-甲醛 苯并噁唑,5,7-二(1,1-二甲基乙基)-2-乙烯基- 苯并噁唑,5,7-二(1,1-二甲基乙基)-2-乙基- 苯并噁唑,4,7-二氯-2-(氯甲基)- 苯并噁唑,2-叠氮- 苯并噁唑,2-(氯甲基)-4,7-二氟- 苯并[d]恶唑-7-甲酸甲酯 苯并[d]恶唑-5-硼酸频哪醇酯 苯并[d]噁唑-6-甲醛 苯并[d]噁唑-2-羧酸甲酯 苯并[d]噁唑-2-甲醇 苯并[D]恶唑-7-胺 苯并[D]噁唑-4-基氨基甲酸叔丁酯 苯并[D]噁唑-2-羧酸钾 苯并-13C6-噁唑 离子载体 碘化二氢2-[3-(5,6-二氯-1,3-二乙基-1,3--2H-苯并咪唑-2-亚基)丙-1-烯基]-3-乙基-5-苯基苯并噁唑正离子 硫代偏糖醛 甲酰胺,N-乙基-N-[6-[(3-甲酰基苯氧基)甲基]-2-苯并噁唑基]- 甲酰胺,N-[6-(溴甲基)-2-苯并噁唑基]-N-乙基- 甲基硫酸1-甲基-8-[(甲基氨基甲酰)氧代]喹啉正离子 甲基6-氨基-1,3-苯并恶唑-2-羧酸酯 甲基2-氨基-1,3-苯并恶唑-5-羧酸酯 甲基1,3-苯并恶唑-2-基乙酸酯 甲基-2-乙基-1,3-苯并唑-5-羧酸乙酯 甲基-1,3-苯并唑-5-羧酸乙酯 环戊二烯并[e][1,3]恶嗪-5,6-二胺 环戊二烯并[d][1,3]恶嗪-6,7-二胺 溴氯唑酮 溴化二氢2-[3-[1-[4-[(乙酰氨基)磺基基]丁基]-5,6-二氯-3-乙基-1,3--2H-苯并咪唑-2-亚基]丙-1-烯基]-3-乙基-5-苯基苯并噁唑正离子 氰基二硫代亚氨酸(6-氯-2-氧代-3(2H)-苯并恶唑基)甲基甲基酯 氰基-二硫代亚氨酸甲基(2-氧代-3(2H)-苯并恶唑基)甲基酯